Magnolol inhibits the resistance of ESBLs E. coli to fourth-generation cephalosporins in vitro and in vivo

Key Points

• Magnolol demonstrates effectiveness in reducing ESBLs E. coli resistance to fourth-generation cephalosporins.
• In vitro assays reveal a significant reduction in resistance levels after magnolol treatment.
• The study utilizes both in vitro and in vivo methods to validate magnolol's efficacy against resistant strains.
• This finding suggests magnolol could serve as a promising adjuvant in treating resistant bacterial infections.